Company: NCEL
Filing Date: 2025-07-18
Form Type: 425
Source: 0001213900-25-065658
Chunk: 2

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: 425
Chunk 2
---
 any sale of securities in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities
shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

<div align='center'>1</div>

Additional Information about the Transaction and Where to Find It

In
connection with the proposed transaction, the Company filed a registration statement on Form F-4 on December 30, 2024, including a proxy
statement/prospectus, with the SEC (the “F-4 Registration Statement”), and subsequent Amendments to the F-4 Registration Statement
on March 3, 2025, March 31, 2025, June 9, 2025 and June 23, 2025. The Company may also file other relevant documents regarding the proposed
transaction with the SEC, including an amendment to the F-4 Registration Statement. This document is not a substitute for the proxy statement/prospectus
or any other document that the Company may file with the SEC. The proxy statement (if and when available) will be mailed to shareholders
of the Company. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT
MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY
BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders
will be able to obtain free copies of the proxy statement/prospectus (if and when available) and other documents containing important
information about the Company and the proposed transaction, once such documents are filed with the SEC through the website maintained
by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by the Company will be available free of charge on the Company’s
website at www.nlspharma.com.

Participants in the Solicitation

The
Company and certain of its respective directors and executive officers may be deemed to be participants in the solicitation of proxies
from the Company’s shareholders in respect of the proposed transaction. Information about the directors and executive officers of
the Company, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in